Press Releases

Press Releases

November 15, 2016
Researchers will present key findings on the development of sensitive predictive biomarkers to establish therapeutic strategies for neurodegenerative diseases; Company will join forces with UmanDiagnostics to provide an ultrasensitive assay for Nf-L
May 16, 2017
CEO to discuss promising role of protein biomarkers in advancing detection and treatment of traumatic brain injury
Business Wire
Discussion will be led by Dr. Edward Wild and Lauren Byrne from the UCL Institute of Neurology, with introductory remarks from Kevin Hrusovsky, Executive Chairman and CEO, Quanterix
DENVER – A new test could reliably detect early increases in prostate specific antigen (PSA) levels – a biomarker commonly used to measure the recurrence of prostate cancer – in men who have undergone prostate cancer-treating surgery. Earlier detection of these rising levels would allow men with…
CAMBRIDGE, MA – July 21, 2011 – Quanterix Corporation, an in vitro diagnostics (IVD) company providing life science researchers and IVD labs single molecule technology with unprecedented sensitivity and precision, announced that the analytical performance of AccuPSA™, a fifth–generation digital…
CAMBRIDGE, MA – January 5, 2012 – Quanterix Corporation, a company enabling a new generation of molecular diagnostic tests based on its revolutionary Single Molecule Array (SiMoA™) technology, announced today a strategic investment and technology development agreement with In–Q–Tel (IQT), the…

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more